자가면역질환의 제휴 및 라이선스 계약(2016-2026년)

Understand the autoimmune partnering landscape using intelligence from 1,066 real-world collaboration and licensing deals.

Autoimmune Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 1,066 partnering deals involving autoimmune assets, technologies and development programs.

Autoimmune disease represents a broad and active area of life sciences partnering, encompassing multiple therapeutic targets, development stages, technologies and deal structures.

The report brings this activity together in one resource, enabling users to understand who is partnering, what is attracting deal activity, how transactions are structured, what financial terms have been disclosed and how partnering activity differs across autoimmune targets and technologies.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with detailed financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in autoimmune partnering.

Understand the autoimmune partnering landscape

The report analyzes autoimmune dealmaking from 2016 to 2026, including:

• Trends in autoimmune partnering activity by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Autoimmune therapeutic target
• Most active autoimmune dealmakers
• Leading deals by disclosed value
• How autoimmune partnering activity is evolving
• This enables users to understand where activity is concentrated and identify the companies, technologies, development stages and therapeutic targets attracting partnering interest.
• Benchmark autoimmune deal financials
• The economics of autoimmune deals can vary significantly according to the asset, development stage, technology, rights granted and overall structure of the transaction.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Individual transactions can then be investigated in greater depth to understand the context behind the disclosed economics.
• This provides users with real-world reference points when preparing internal benchmarks, evaluating opportunities or entering partnering discussions.
• Financial benchmarks are most valuable when considered alongside the structure and circumstances of comparable deals rather than as standalone averages, and the report provides the wider transaction intelligence needed to establish that context.
• Identify leading autoimmune dealmakers and prospective partners
• The report identifies the most active companies in autoimmune dealmaking and provides extensive transaction histories that enable users to investigate their partnering activity.

This can help users identify:

• Companies actively seeking autoimmune opportunities
• Potential licensing and collaboration partners
• Organizations repeatedly partnering in particular therapeutic areas
• Companies active at relevant stages of development
• Dealmakers showing interest in specific technologies or approaches
• Competitors pursuing similar external innovation strategies
• For companies seeking to partner an autoimmune asset or technology, previous deal activity can provide valuable evidence of which organizations have demonstrated a genuine appetite for comparable opportunities.
• Compare deals across therapeutic targets
• Autoimmune is not a single homogeneous partnering market.
• The report provides analysis by autoimmune therapeutic target, enabling users to investigate differences in partnering activity across individual areas of autoimmune disease and identify transactions most relevant to a particular program or strategic interest.
• This helps users move beyond broad autoimmune benchmarks and focus on the subset of transactions most relevant to their own opportunity.
• Understand how autoimmune agreements are structured
• The report includes collaboration, licensing and other partnering transactions, enabling users to examine how companies have structured relationships around autoimmune assets and technologies.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a new autoimmune partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected autoimmune transactions.

These agreements can reveal substantially more detail than headline announcements alone, helping users understand how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating an autoimmune collaboration or licensing transaction, access to real agreement language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive autoimmune deal directory
• The report includes a comprehensive directory of 1,066 autoimmune collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable autoimmune transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking opportunities across particular autoimmune targets, technologies and stages of development.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable autoimmune assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and potential partners are building autoimmune pipelines through external innovation.
• Competitive and Market Intelligence teams
• Track activity by company, development stage, technology and therapeutic target to understand evolving partnering priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide autoimmune intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying autoimmune deal intelligence to the customer's own asset, technology, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z
• Deal Directory - Autoimmune deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016